Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-HRV Oral Vaccine
- Development stage
- Preclinical
- Lead developer
- CHAIN Biotechnology
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
**Anti-HRV Oral Vaccine** is a preclinical oral rotavirus vaccine being developed by CHAIN Biotech in collaboration with the University of Oxford for prevention of human rotavirus infection. The candidate uses CHAIN Biotech's CADD platform, an engineered non-pathogenic *Clostridium butyricum* live bacterial spore and vector system designed for oral delivery to the lower gastrointestinal tract. It expresses or delivers human rotavirus antigens to induce protective mucosal and systemic immune responses, with a stated development goal of improving vaccine performance in malnourished and low-income populations where conventional rotavirus vaccine efficacy may be reduced.
- Other names
- Anti-Human Rotavirus oral vaccineCADD oral HRV vaccine
02
Targets
RVA (Rotavirus A)
Beyond the preview
Go deeper on Anti-HRV Oral Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-HRV Oral Vaccine.